Table 1. Baseline patient and tumour characteristics by trial interventions.
Platinum-based regimen
|
Number of drugs
|
|||||||
---|---|---|---|---|---|---|---|---|
Yes (N=216)
|
No (N=217)
|
2-Drugs (N=212)
|
3-Drugs (N=221)
|
|||||
No. | % | No. | % | No. | % | No. | % | |
Median age (range), years | 63 (29–79) | 64 (35–77) | 62.5 (29–77) | 64 (41–79) | ||||
Gender | ||||||||
Male | 170 | 79 | 176 | 81 | 170 | 80 | 176 | 80 |
Female | 46 | 21 | 41 | 19 | 42 | 20 | 45 | 20 |
ECOG PS | ||||||||
0 | 132 | 61 | 132 | 61 | 128 | 60 | 136 | 62 |
1 | 74 | 34 | 77 | 35 | 75 | 35 | 76 | 34 |
2 | 10 | 5 | 8 | 4 | 9 | 4 | 9 | 4 |
Stage | ||||||||
IIIB | 46 | 21 | 42 | 19 | 45 | 21 | 43 | 19 |
IV | 170 | 79 | 175 | 81 | 167 | 79 | 178 | 81 |
Method of diagnosis | ||||||||
Histology | 145 | 67 | 144 | 66 | 137 | 65 | 152 | 69 |
Cytology | 62 | 29 | 63 | 29 | 65 | 31 | 60 | 27 |
Missing value | 9 | 4 | 10 | 5 | 10 | 4 | 9 | 4 |
Histology | ||||||||
Adenocarcinoma | 90 | 42 | 92 | 42 | 90 | 42 | 92 | 42 |
Squamous | 59 | 27 | 60 | 28 | 55 | 26 | 64 | 29 |
Large cell | 6 | 3 | 2 | 1 | 4 | 2 | 4 | 2 |
NOS | 61 | 28 | 63 | 29 | 63 | 30 | 61 | 27 |
Abbreviations: ECOG=Eastern Cooperative Oncology Group; NOS=not otherwise specified; PS=performance status.